On April 1, 2026, Axsome Therapeutics, Inc. announced the acquisition of a selective PDE10A inhibitor named Balipodect, aimed at treating schizophrenia and other neuropsychiatric conditions. This acquisition reflects Axsome's strategic efforts to expand its product offerings in therapeutic areas.